[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Synusight Biotech (Shanghai) Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100637666","phase-1-a-study-to-evaluate-satety-tolerability-biodistribution-radiation-dosimetry-and-pharmacokinetics-of-sst001-in-healthy-volunteers-patients-with-pd-and-patients-with-msa-100637666",false,"NCT07604116","A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA","A Non-Randomized, Open-Label Phase I Study to Evaluate the Safety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With Multiple System Atrophy, and Patients With Parkinson's Disease","Inclusion Criteria:\n\n* Sign the informed consent form approved by IEC.\n* Male or female participants aged ≥40 years old.\n* Adequate organ functions.\n* Proper contraception methods.\n* Willingness to follow the study procedures.\n* Additional inclusion criteria for healthy volunteers: Good health status; no history of motor disorders or cognitive disorders.\n* Additional inclusion criteria for MSA: Diagnosed with clinically established or clinically probable MSA according to the MDS MSA criteria (2022). If previously treated, the treatment regimen for MSA must have been stable for at least 4 weeks with no planned adjustments in the near term.\n* Additional inclusion criteria for PD: Diagnosed with clinically established or clinically probable PD according to the MDS PD criteria (2015). If previously treated, the treatment regimen for PD must have been stable for at least 4 weeks with no planned adjustments in the near term.\n\nExclusion Criteria:\n\n* Being pregnant or lactating.\n* History of other severe neurological disorders.\n* History of serious or uncontrolled medical condition.\n* Active HBV\u002FHCV\u002FHIV infection, etc.\n* History of abuse of drugs or alcohol within 1 year.\n* Allergy to the study drug.\n* Intolerance to PET\u002FCT or MRI (e.g. claustrophobia).\n* Any interventional clinical studies within 30 days.\n* Radiation exposure dose exceeding 50 mSv\u002Fyear.\n* Prior therapy targeting α-Syn.\n* Other ineligible conditions for this study.",true,"ALL","40 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The non-randomized, open-label phase I study aims to evaluate the safety, tolerability, biodistribution, radiation dosimetry, and pharmacokinetics of SST001 in healthy volunteers, patients with MSA and patients with PD.",[27,28],"Multiple System Atrophy (MSA)","Parkinson's Disease (PD)","RECRUITING","2026-06-29",{"date":32,"type":33},"2026-06-30","ACTUAL",{"date":35,"type":33},"2026-06-15",{"date":37,"type":21},"2027-02",{"name":39,"class":40},"Synusight Biotech (Shanghai) Co., Ltd.","INDUSTRY",2,""]